Press Releases

A recent study published in the Journal of American Nutrition Association shows that bis hexanoyl (R)-1,3-butanediol (BH-BD), the active ingredient in Metabolic Switch®, induces ketosis.

Juvenescence Ltd., a biopharmaceutical company, is pleased to announce its new equity investment in MDI Therapeutics, Inc. a company developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative...

Morphoceuticals Inc., a portfolio company of Juvenescence Ltd., hailed the results of a long-term study published by its founders in Science Advances showing the successful regeneration of limbs in Xenopus laevis (African clawed frog)....

Ketosis is featured in wellness conversations—from immunity to brain function to longevity. MGB talks ketosis with Dr. Brianna Stubbs, DPhil, scientist who helped develop the breakthrough ketone ester drink Metabolic...

January 5 is National Keto Day. Started two years ago by The Vitamin Shoppe, the day serves to bring awareness to the ketogenic diet and its health benefits.

LyGenesis announced that it has achieved positive in vitro results of a novel combination drug-biologic product for patients with inborn errors of metabolism, adding these orphan pediatric indications to its...

Juvenescence Ltd., a longevity biotech and life sciences company announced the launch of Metabolic Switch®, an evidence-based, breakthrough C6 Ketone Di-ester drink that puts the consumer in ketosis to promote...

Juvenescence announces that Dr. Grazia Piizzi has joined its Executive Management Team as Chief Scientific Officer.

AgeX Therapeutics announced the online publication of data relating to regeneration, aging, and cancer in bioRxiv.

AgeX Therapeutics and LyGenesis announced today that they will proceed to negotiate an agreement for a merger of the two companies.

LyGenesis, Inc. announced that the FDA has cleared its Investigational New Drug application and a study will be conducted on the safety and efficacy of its first-in-class novel cell therapy...

AgeX Therapeutics announced that ImStem has obtained a non-exclusive, royalty-bearing sublicense from AgeX for development of ImStem’s investigational product candidate IMS001 for development in COVID-19 and ARDS from other causes....